Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Multiple Myeloma 15Lymphoma, B-Cell, Marginal Zone 5Neoplasms, Plasma Cell 3Lymphoma 3Recurrence 2Pseudomyxoma Peritonei 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Infections 1Helicobacter Infections 1Chemotherapy Effect 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Cachexia 1Appendiceal Neoplasms 1

Interventions

Carboplatin 44Paclitaxel 42Cisplatin 20Topotecan 17Gemcitabine 16Docetaxel 13Bevacizumab 13liposomal doxorubicin 7olaparib 6Cyclophosphamide 6pembrolizumab 5Surgical Procedures, Operative 5Filgrastim 5Etoposide 5Drug Therapy 5Amifostine 5sargramostim 4oregovomab 4catumaxomab 4anlotinib 4Imatinib Mesylate 4Hyperthermic Intraperitoneal Chemotherapy 4rucaparib 3pegfilgrastim 3niraparib 3ixabepilone 3aldesleukin 3Standard of Care 3Peripheral Blood Stem Cell Transplantation 3Oxaliplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Ovarian Epithelial × Clarithromycin × Clear all
NCT07341100 2026-06-01

Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin on the PK of SKB264 in OC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Phase 2 Active not recruiting
20 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡